United Therapeutics UTHR
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–
Earnings
Average move on report day±4.7%last 16 reports
Closed higher11 of 1669% of the time
Best reaction+13.0%
Worst reaction-10.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 4 Nov 2026 | Pre Market | ±6.6% | +1.19% | Within range |
| 2026/Q2 | 5 Aug 2026 | Pre Market | ±6.4% | +0.06% | Within range |
| 2026/Q1 | 6 May 2026 | Pre Market | ±7.6% | +4.29% | Within range |
| 2025/Q4 | 25 Feb 2026 | Pre Market | ±9.1% | +13.03% | Bigger than priced |
| 2025/Q3 | 29 Oct 2025 | Pre Market | ±9.9% | +9.63% | Within range |
| 2025/Q2 | 30 Jul 2025 | Pre Market | ±9.5% | -5.25% | Within range |
| 2025/Q1 | 30 Apr 2025 | Pre Market | ±7.4% | +0.77% | Within range |
| 2024/Q4 | 26 Feb 2025 | Pre Market | ±9.1% | -10.80% | Bigger than priced |
| 2024/Q3 | 30 Oct 2024 | Pre Market | ±7.4% | +2.44% | Within range |
| 2024/Q2 | 31 Jul 2024 | Pre Market | ±8.0% | -7.18% | Within range |
| 2024/Q1 | 1 May 2024 | Pre Market | ±8.2% | +8.88% | Bigger than priced |
| 2023/Q4 | 21 Feb 2024 | Pre Market | ±8.8% | +2.34% | Within range |
| 2023/Q3 | 1 Nov 2023 | Pre Market | ±7.2% | +0.55% | Within range |
| 2023/Q2 | 2 Aug 2023 | Pre Market | ±5.8% | +0.30% | Within range |
| 2023/Q1 | 3 May 2023 | Pre Market | ±8.5% | -4.54% | Within range |
| 2022/Q4 | 22 Feb 2023 | Pre Market | ±8.9% | -4.51% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q3
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$832.50M+4.1% YoY
Operating profit$241.30M-38.0% YoY
Net profit$258.60M-23.6% YoY
Diluted EPS$5.71-20.3% YoY
Free cash flow$125.80M-64.2% YoY
Operating cash flow$306.50M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin86.3%
Operating margin39.4%
Net margin38.6%
Return on equity19.1%
Return on assets17.1%
Return on invested capital17.4%
Current ratio4.61
Liabilities / assets10.8%
Cash & investments$2.07B
Net cash (debt)$2.07B
Free cash flow / sales27.0%
No comments yet — be the first to weigh in on UTHR.
Sign in to join the discussion.